Atrial fibrillation: market opportunity, technology landscape and investment outlook
A unified view of the AF market and the technologies reshaping it, 2025–2035.
Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting approximately 37.5 million people worldwide, with prevalence projected to rise by more than 60% by 2050. The global AF market, spanning pharmaceuticals, ablation technologies, LAAC devices, and digital health, stands at approximately $29.7 billion in 2025 and is projected to reach $80.1 billion by 2035, a 10.4% CAGR.
The study maps two simultaneous disruptions: the move from thermal to pulsed field ablation (PFA) in correction, and the emergence of metabolic and gene-therapy approaches that aim to prevent or reverse the disease. It closes with an investment framework by segment.
Key findings
- The AF ablation market is valued at about $8 billion in 2025 and, at roughly 12% CAGR, is projected to reach about $24.8 billion by 2035.Global Market Insights; Market Growth Reports
- Pulsed field ablation is projected to grow from $322 million in 2025 to $5.4 billion by 2035, a 28.3% CAGR.Roots Analysis, Global Pulsed Field Ablation Market Share Report, 2025
- More than 900,000 PFA cases have been performed worldwide with zero atrioesophageal fistulas, against roughly 1 in 1,000 with thermal ablation.
- Four incumbents (Medtronic, J&J Biosense Webster, Boston Scientific, and Abbott) hold about 80% of the ablation market; the share held by other and emerging players is projected to rise from about 8% to about 15% by 2035.Kraus Advisors estimates based on published physician surveys and market reports
- GLP-1 receptor agonists show converging evidence of AF risk reduction, including an 18% relative reduction across 24 RCTs and 42% for semaglutide across 10 RCTs.Published meta-analyses cited in the study
- Cumulative AF ablation revenue over 2025–2035 is estimated at about $165 billion, and the total AF market's cumulative opportunity exceeds $500 billion.Kraus Advisors calculations from the cited growth rates
Method
Market sizes and growth rates are drawn from published market research (Future Market Insights, Global Market Insights, Roots Analysis, Coherent Market Insights, and others) and the clinical literature. The 2035 segment mix, competitive share, and cumulative figures are Kraus Advisors projections built on those sources; each figure's sources and assumptions are footnoted in the study. The study is for informational purposes only and does not constitute investment advice.
Cite this study
Kraus Advisors (2026). Atrial Fibrillation: Market Opportunity, Technology Landscape & Investment Outlook, 2025–2035. Applied Study AS 2026-02, April 2026. krausadvisors.com/insights/atrial-fibrillation-market-outlook/